Equities

Mizuho Medy Co Ltd

4595:TYO

Mizuho Medy Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)3,390.00
  • Today's Change-30.00 / -0.88%
  • Shares traded26.70k
  • 1 Year change+63.37%
  • Beta1.9799
Data delayed at least 20 minutes, as of May 22 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MIZUHO MEDY CO., LTD. is a Japan-based company principally engaged in-vitro diagnostic pharmaceuticals business. The Company mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.

  • Revenue in JPY (TTM)11.34bn
  • Net income in JPY4.00bn
  • Incorporated1977
  • Employees180.00
  • Location
    Mizuho Medy Co Ltd5-4, Fujinoki-machiTOSU-SHI 841-0048JapanJPN
  • Phone+81 942850303
  • Fax+81 942850312
  • Websitehttps://www.mizuho-m.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Microwave Chemical Co Ltd1.86bn-944.90m18.18bn59.00--21.24--9.76-60.75-60.75120.5354.810.749531.734.31---38.01---52.71--60.13---50.71--1.8126.200.3803--53.32---1,353.29------
TAIKO PHARMACEUTICAL CO LTD6.33bn-2.90bn19.85bn208.00--2.65--3.14-58.49-58.49129.20148.040.4622.043.4430,432,690.00-21.14---26.00--44.27---45.75--2.92--0.2811--21.43--26.23------
Astena Holdings Co Ltd52.63bn1.62bn20.20bn1.40k12.030.68245.250.383940.9840.981,332.61722.460.81273.312.7637,482,540.002.492.494.444.4432.2725.333.062.320.8713--0.351744.924.73-2.85100.61-3.8538.5411.38
Medical Data Vision Co Ltd6.25bn688.02m20.29bn262.0028.154.8626.843.2518.0118.01163.57104.341.15282.077.8423,847,790.0012.1816.1617.0120.8877.4381.9010.5515.522.7213.480.0019.985.1512.4012.4869.75-23.95--
Fuso Pharmaceutical Industries Ltd55.41bn1.38bn21.39bn1.31k14.160.52757.460.386159.77159.776,435.264,290.490.74743.122.43--1.861.913.063.0924.9826.922.492.691.0454.560.257641.178.613.76-14.219.029.13-2.64
Cuorips Inc23.10m-632.18m24.90bn46.00--4.15--1,077.84-86.04-86.043.14752.260.00474.6617.57---12.94---13.30--41.69---2,736.49--33.80-------39.65---39.84------
Pharma Foods International Co., Ltd.65.08bn4.76bn25.68bn670.005.352.694.780.3945165.17165.172,257.80327.801.842.2212.7197,135,820.0013.448.4048.1219.2079.8981.347.323.850.844991.330.683928.2613.9453.90923.8057.9251.63--
StemRIM Inc2.35bn179.40m28.54bn44.00135.552.91--12.14-0.1097-0.109737.43159.710.2453----53,409,090.001.87-6.711.89-6.83----7.63-45.8078.90652.720.00--10,128.0663.68108.64------
SanBio Co Ltd0.00-2.64bn31.23bn29.00--11.07-----40.50-40.500.0041.110.00----0.00-43.74-42.00-52.38-48.88-------4,790.72----0.1923------52.44--53.94--
Mizuho Medy Co Ltd11.34bn4.00bn32.58bn180.008.152.137.772.87419.74419.741,190.621,607.770.64841.872.9962,999,830.0022.8631.4626.2339.7873.4174.8535.2533.646.41--0.0034.83-37.4911.34-51.8532.64-17.7432.85
Koa Shoji Holdings Co Ltd22.67bn2.87bn34.23bn297.0011.931.519.561.5172.4572.45572.11573.530.78785.562.6276,317,420.009.987.9112.089.9329.9528.7412.6610.483.8636.550.114219.648.358.2713.9029.60-21.2615.52
Daito Pharmaceutical Co Ltd45.19bn3.28bn36.29bn1.01k11.120.69815.340.8031207.85207.852,864.813,311.810.61931.812.6544,701,280.004.356.995.649.2921.3822.717.038.831.15--0.123117.083.772.49-22.883.437.4812.70
Fuji Pharma Co Ltd43.05bn5.92bn37.58bn1.62k6.230.83764.080.8728243.57243.571,771.381,812.380.50711.343.2126,558,910.006.974.1010.565.5839.7842.4113.757.550.5895--0.382631.1715.421.5227.410.370919.045.73
Seikagaku Corp36.21bn2.19bn44.09bn976.0019.360.585811.321.2240.0840.08663.801,324.810.46012.065.02--2.780.42613.050.467846.6054.186.040.98144.47--0.0055415.528.244.99-2.24-0.522430.280.00
Data as of May 22 2024. Currency figures normalised to Mizuho Medy Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

1.94%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 09 May 202456.80k0.60%
Mellon Investments Corp.as of 09 May 202447.00k0.49%
American Century Investment Management, Inc.as of 09 May 202436.30k0.38%
BlackRock Fund Advisorsas of 09 May 202416.50k0.17%
Mitsubishi UFJ Asset Management Co., Ltd.as of 27 Feb 20238.00k0.08%
Lazard Asset Management LLCas of 31 Dec 20225.50k0.06%
Victory Capital Management, Inc. (Investment Management)as of 31 Jan 20244.60k0.05%
Asset Management One Co., Ltd.as of 09 May 20243.70k0.04%
Dimensional Fund Advisors Ltd.as of 09 May 20243.58k0.04%
DFA Australia Ltd.as of 31 Mar 20242.49k0.03%
More ▼
Data from 31 Mar 2024 - 16 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.